Home > Compound List > Product Information
Terazosin_Molecular_structure_CAS_63590-64-7)
Click picture or here to close

Terazosin

Catalog No. DB01162 Name DrugBank
CAS Number 63590-64-7 Website http://www.ualberta.ca/
M. F. C19H25N5O4 Telephone (780) 492-3111
M. W. 387.4329 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 1033

SYNONYMS

IUPAC name
6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine
IUPAC Traditional name
6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine
Brand Name
Vasomet
Blavin
Fosfomic
Heitrin
Hytracin
Hytrin
Hytrinex
Itrin
Flumarc
Urodie
Vicard
Synonyms
Terazosina [INN-Spanish]
Terazosinum [INN-Latin]
Terazosine [INN-French]
Abbott 45975
Terazosin HCl
Terazosin hydrochloride
Terazosine
Trazosin HCl

DATABASE IDS

CAS Number 63590-64-7
PubChem SID 46509129
PubChem CID 5401

PROPERTIES

Hydrophobicity(logP) 1
Solubility 29.7mg/mL

DETAILS

Description (English)
Item Information
Drug Groups approved
Description Terazosin is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.
Indication For the treatment of symptomatic BPH and mild to moderate hypertension.
Pharmacology Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an α-adrenergic blocking agent, terazosin is used to treat hypertension and BPH. Terazosin produces vasodilation and reduces peripheral resistance but in general has only a slight effect on cardiac output. The antihypertensive effect with chronic dosing is not usually accompanied by reflex tachycardia.
Toxicity LD50=259.3mg/kg (IV in mice)
Affected Organisms
Humans and other mammals
Biotransformation Hepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity.
Absorption Essentially completely absorbed in man (90% bioavailability).
Half Life 12 hours
Protein Binding 90-94%
Elimination Approximately 10% of an orally administered dose is excreted as parent drug in the urine and approximately 20% is excreted in the feces.
References
Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

REFERENCES

  • Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. Pubmed